Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction involving Dr. P J T Vallance, a Person Discharging Managerial Responsibilities. On April 29, 2015, GSK was advised that Dr. Vallance's Connected Person, Dr. S Dexter, acquired 293 GSK Ordinary Shares. The acquisition price was 1,627 pence per share. This transaction resulted from the re-investment of the dividend paid to shareholders on April 9, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Transaction Date: April 29, 2015 (Notification date).
- Individual Involved: Dr. S Dexter (Connected Person of Dr. P J T Vallance).
- Transaction Type: Acquisition of 293 Ordinary Shares via dividend re-investment.
- Share Price: 1,627 pence per share.
- Dividend Reference: Linked to the dividend paid on April 9, 2015.